Publication & Citation Trends
Publications
0 total
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors OA
Cited by 30
Semantic Scholar
Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens
Cited by 24
Semantic Scholar
Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screens OA
Cited by 5
Semantic Scholar
Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death
Cited by 1
Semantic Scholar
KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors OA
Cited by 6
Semantic Scholar
255 ExPRESSTM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTILTMproduct OA
Cited by 1
Semantic Scholar
Abstract ND01: KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies
Cited by 7
Semantic Scholar
204 KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors OA
Cited by 5
Semantic Scholar
Research Topics
CRISPR and Genetic Engineering
(35)
PARP inhibition in cancer therapy
(16)
Advanced biosensing and bioanalysis techniques
(9)
RNA modifications and cancer
(9)
DNA Repair Mechanisms
(8)
Affiliations
Brigham and Women's Hospital
Novartis (Switzerland)
Foundation for Biomedical Research
Target (United States)
Howard Hughes Medical Institute